28-Mar-2024
No headlines found.
Adicet Bio Reports Inducement Grant under Nasdaq Listing Rule 5635(c)(4)
Business Wire (Thu, 28-Mar 5:19 PM ET)
Business Wire (Tue, 19-Mar 4:10 PM ET)
Business Wire (Mon, 11-Mar 7:00 AM ET)
Business Wire (Mon, 5-Feb 4:01 PM ET)
Business Wire (Thu, 25-Jan 4:01 PM ET)
Adicet Bio, Inc. Announces Pricing of Public Offering
Business Wire (Mon, 22-Jan 11:43 PM ET)
Adicet Bio, Inc. Announces Proposed Public Offering
Business Wire (Mon, 22-Jan 4:28 PM ET)
Adicet Provides Corporate Update and Highlights Strategic Priorities for 2024
Business Wire (Thu, 4-Jan 7:00 AM ET)
Adicet Bio to Host Conference Call to Provide Updates on its Clinical Pipeline and Corporate Outlook
Business Wire (Wed, 3-Jan 4:01 PM ET)
Adicet Bio Inc is a clinical-stage biotechnology company discovering and developing allogeneic gamma delta T cell therapies for cancer and other diseases. Its lead product candidate, ADI-001, a first-in-class allogeneic gamma delta T cell therapy expressing a CAR targeting CD20, is being developed for the potential treatment of autoimmune diseases and relapsed or refractory aggressive B cell non-Hodgkin's lymphoma. Their pipeline also includes its lead preclinical candidate, ADI-270, an armored gamma delta CAR T cell product candidate targeting renal cell carcinoma, with potential for other CD70+ solid tumor and hematological malignancies indications.
Adicet Bio trades on the NASDAQ stock market under the symbol ACET.
As of March 28, 2024, ACET stock price climbed to $2.35 with 490,858 million shares trading.
ACET has a beta of 0.71, meaning it tends to be less sensitive to market movements. ACET has a correlation of 0.00 to the broad based SPY ETF.
ACET has a market cap of $193.06 million. This is considered a Micro Cap stock.
Last quarter Adicet Bio reported $0 in Revenue and -$.69 earnings per share. This fell short of revenue expectation by $-620,000 and met earnings estimates .
In the last 3 years, ACET stock traded as high as $21.87 and as low as $1.10.
The top ETF exchange traded funds that ACET belongs to (by Net Assets): VTI, IWM, IWN, VXF, CNCR.
ACET stock has underperformed the market in the last year with a return of -60.3%, while SPY returned +33.6%. This shows that you would have done better investing in the overall market (through SPY) over the last year than in ACET shares. However, ACET has outperformed the market in the last 3 month and 2 week periods, returning +33.5% and +4.4%, while SPY returned +10.1% and +1.7%, respectively. This indicates ACET has been having a stronger performance recently.
ACET support price is $2.22 and resistance is $2.44 (based on 1 day standard deviation move). This means that using the most recent 20 day stock volatility and applying a one standard deviation move around the stock's closing price, stastically there is a 67% probability that ACET stock will trade within this expected range on the day.